N
Novai
Retinal biomarker with AI, advancing drug development for AMD and glaucoma therapeutics
About Novai
Novai is a healthcare technology startup that operates in the ophthalmic disease detection and treatment market. The company is developing a novel technology called DARC (Detection of Apoptosing Retinal Cells), which combines a biologic molecule (Annexin-776) with artificial intelligence (AI) to detect and treat eye diseases in real-time. This technology is primarily aimed at pharmaceutical companies and biotech firms involved in drug development for ophthalmic conditions.
Read full description
Novai's business model revolves around supporting these companies in de-risking and accelerating their clinical trials. The DARC technology aids in early detection of glaucoma, enabling active disease management and improving patient outcomes. Additionally, the company is exploring the use of the DARC biologic molecule as a targeted drug delivery vehicle, which could potentially overcome biological barriers that impede drug delivery to the eye and brain.
The company's technology also offers a unique biomarker that rapidly measures the impact of current and future therapeutics and interventions. This feature helps stratify patients in clinical trials, creating enriched patient cohorts and identifying non-responders to existing and new interventions. This can help pharmaceutical clients avoid ineffective medical management and de-risk their ophthalmic trials.
Novai's technology can be tailored to the unique design of each client, maximizing the success of their glaucoma or AMD (Age-related Macular Degeneration) trial. By delivering DARC in a clearly outlined full-service model, Novai can boost efficiency, quickly determine efficacy, and save clients time and money.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Reading, United Kingdom
- Employees
- 16
- Open positions
- 1
- Dealroom signal
- 73.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Eye Diseases, Core AI, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio
- Technology
- Artificial Intelligence, Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2025 | $243K | $1.7M | Undisclosed | ↗ |
| SEED✓Equity / VC | Dec 2024 | $330K | $1.3M | SFC Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Novai is 1.1K monthly website visits, down 73.2% over the last three months. Novai's team declined 20% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
SFC Capital
Ascension Ventures
Other known investors5 additional known investors
University College London
AI Visionaries
Minerva Business Angel Network
Serge Chiaramonte
Syndicate Room
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novai on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novai’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.